Genaera Corporation |

Genaera Corporation Announces Second Quarter Financial Results
August 11th, 2008
Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
July 25th, 2008
Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
July 14th, 2008
Genaera Corporation Elects Paul K. Wotton to Board of Directors
June 30th, 2008

American Diabetes Association Meeting
New Orleans, LA
June 6th, 2008 -- June 10th, 2008

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. We have significant market opportunities with a first-in-class molecule that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes. In addition, we have a value-driven, fully out-licensed partnership with MedImmune for a second core program.

MSI-1436, the core internal asset of Genaera, is a clinical candidate in Phase 1 development for the treatment of obesity and has applicability in type 2 diabetes. Genaera initiated its first-in-man clinical studies in 2Q07.
MEDI-528 the second core asset out-licensed to MedImmune/Astra Zeneca is being evaluated in Phase 2 clinical studies with applicability in the treatment of asthma. Please refer to www.medimmune.com for status of this program.